Eric Brandt

October 17, 2026

RBC Lowers Gen Digital Price Target to $24. RBC Capital lowered its price target for Gen Digital to $24 while maintaining a Sector Perform rating. This move aligns with the stock's recent technical support level near $24.51. Meanwhile, Gen Digital is set to participate in upcoming investor conferences, and analysts continue to debate the potential of its AI-ready insurance marketplace.

October 16, 2026

Lam Research Q1 Earnings Preview Amid Chip Equipment Sector Slump. Lam Research is preparing for its Q1 earnings report while the broader chip equipment sector faces pressure from AI spending concerns. The stock has recently touched its 200-day moving average, a technical level that often signals a potential trend change. Investors are watching to see if the company's strong return on invested capital can offset the current market volatility.

October 11, 2026

McKesson moves to acquire Option Care Health in $5.8B deal. Option Care Health is the target of a $5.8 billion acquisition by McKesson, which has lifted the stock in recent trading. The deal is under legal review, and several analysts have lowered their ratings, with UBS moving to neutral and William Blair to market‑perform. The mixed reactions reflect both the premium offered and the uncertainties around regulatory approval.

October 17, 2026

Nutanix Stock Underperforms Market Amid Broker Analysis. Nutanix shares have recently declined more sharply than the broader market, drawing attention from financial analysts. Recent broker reports suggest the stock is a focus for investment strategies, while comparisons with peers like MongoDB and Google highlight its position among value-oriented tech names. The company's trailing P/E of 12.7 and average analyst target of $77.79 provide context for these ongoing discussions.

October 7, 2026

Truist Securities initiates coverage on Macerich with Buy rating. Truist Securities has initiated coverage on Macerich with a Buy rating and a $26 price target. This move adds to the analyst consensus, which currently averages $27.00 across 15 analysts. The stock currently offers a dividend yield of 6.19%, a factor often considered by income-focused investors.

October 11, 2026

XRAY: Earnings, Target Cut, Expansion, Medicare Coverage. XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.